|Bid||32.60 x 30000|
|Ask||32.80 x 30000|
|Day's range||32.25 - 32.81|
|52-week range||31.28 - 45.77|
|Beta (5Y monthly)||0.31|
|PE ratio (TTM)||24.66|
|Forward dividend & yield||0.90 (2.73%)|
|Ex-dividend date||07 Sept 2023|
|1y target est||N/A|
Australasian pharmaceutical manufacturer EBOS Group said on Wednesday it would not proceed with a potential major transaction in the animal care segment, sending its shares 7% lower. The statement did not name its takeover target but a source with direct knowledge of the matter had said the company was in talks to acquire TPG Capital-backed pets and vets business Greencross. The Australian Financial Review reported that EBOS would pay A$3.75 billion ($2.44 billion) to acquire Greencross, without citing sources, and were set to raise about A$2 billion as early as Wednesday.
EBOS Group's (NZSE:EBO) stock is up by a considerable 12% over the past month. Since the market usually pay for a...
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...